Lutetium Lu 177 Dotatate Demonstrates Efficacy in Advanced Meningioma, Clinical Trials Reveal
Recent clinical research indicates that lutetium Lu 177 dotatate is showing encouraging results in the treatment of advanced intracranial meningiomas, offering a potential new therapeutic option for patients facing this challenging diagnosis.Data presented from ongoing Phase II studies and expert commentary suggest the radiopharmaceutical drug may provide significant benefit for individuals with progressive or recurrent disease.
Meningiomas are the most common primary brain tumors, affecting an estimated 37.8 per 100,000 people in the U.S., according to the National Brain Tumor Society. While many are benign and slow-growing,a subset are aggressive,recurring,or inaccessible to surgical resection or radiation therapy. These patients have limited treatment options,making the emergence of Lutetium Lu 177 dotatate a potentially significant advancement.The drug targets somatostatin receptor 2 (SSTR2),which is often expressed in meningiomas,delivering targeted radiation directly to tumor cells.
A study registered on ClinicalTrials.gov (NCT03971461) is currently evaluating the efficacy of 177Lu-DOTATATE in adults with progressive or high-risk meningioma. Updated as of April 22, 2025, the Phase II trial aims to determine the drug’s safety and anti-tumor activity.
Further bolstering research into the treatment, a second trial (NCT06955169), updated November 13, 2025, is comparing lutetium Lu 177 dotatate to standard of care for patients whose meningioma has returned after prior treatment – a study dubbed MOMENTUM-1.
Dr. Stefan Kurz, speaking on OncLive.com November 22, 2025, discussed the efficacy and safety profile of Lutetium Lu 177 dotatate in advanced intracranial meningioma. His insights align with findings from a Neuro Oncology review published in 2014 (16(6):829-840) which initially explored the potential of somatostatin receptor-targeted therapies in neuroendocrine tumors, laying groundwork for its application in meningioma treatment. The ongoing clinical trials are designed to build upon this foundation and establish the drug’s definitive role in managing this complex disease.
